U.S. Markets closed

Fate Therapeutics, Inc. (FATE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
5.42-0.14 (-2.52%)
At close: 04:00PM EDT
5.70 +0.28 (+5.17%)
After hours: 06:31PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.56
Bid5.44 x 1200
Ask5.75 x 1800
Day's Range5.38 - 5.61
52 Week Range4.02 - 43.12
Avg. Volume4,213,211
Market Cap526.664M
Beta (5Y Monthly)1.46
PE Ratio (TTM)N/A
EPS (TTM)-2.11
Earnings DateMay 02, 2023 - May 08, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.77
  • GlobeNewswire

    Fate Therapeutics to Present at Upcoming March Investor Conferences

    SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will participate in the following upcoming investor conferences: 43rd Annual TD Cowen Health Care Conference on Wednesday, March

  • Insider Monkey

    Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2022 Earnings Call Transcript

    Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2022 Earnings Call Transcript February 28, 2023 Operator: Welcome to the Fate Therapeutics Fourth Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast live on the Investors section of Fate’s website at As a reminder, today’s call […]

  • Simply Wall St.

    Fate Therapeutics Full Year 2022 Earnings: Beats Expectations

    Fate Therapeutics ( NASDAQ:FATE ) Full Year 2022 Results Key Financial Results Revenue: US$96.3m (up 72% from FY 2021...